Acompanhe as Notícias da Recifes

Premium cherry-on-the-vine are poised to take top spot in Britain’s £1bn-a-year tomato marketFor a long time the classic round, red tomato has dominated British salads and sandwiches, but its supremacy is coming under threat as sales of rainbow colours and the upmarket rival “cherry on the vine” take off.“Non-red tomatoes” sales are up 21% this year, a growth rate that far exceeds the overall market, according to Paul Faulkner, of Evesham Vale Growers. Continue reading...

Ambassadors for Gencore Global directed followers to Telegram channels promoting steroids, prescription medicines and experimental peptides‘I felt dizzy’: body builder recalls how drug abuse caught up with himUK becoming ‘wild west’ for experimental peptides, expert warnsFitness influencers who publicly represent a global wellness brand are involved in running an illegal steroid market on social media, the Guardian can reveal.Gencore Global presents itself as a UK-based health and well

Once again a mispriced share price created opening for US raiders to rush inUS private equity firm Apollo enters easyJet bidding warWill any remaining bidders for easyJet please make their way to the boarding gate? In reality, we’ve probably seen the whole cast at this point because the arrival of US private equity firm Apollo, trumping Castlelake’s offer, is a surprise. But the outbreak of a competitive auction will come as a relief to easyJet’s board.For all the fake drama of Castlel

Ministers consider bringing e-cigarette laws in line with tobacco as data shows 20% of teenagers have tried vapingVapes could be sold in plain packaging as part of a range of proposals to stop them being marketed to children.The UK-wide plans also include limiting device colours to white, black or grey, and keeping vapes out of sight in shops, according to the Department of Health and Social Care. Continue reading...

Brent crude dips slightly below $78 a barrel; most Asian stock markets bounce backBritain’s second-biggest drugmaker GSK has also taken a hit from recent drug failures.The Californian biotech Alector has said that GSK has ended their neuroscience collaboration covering ​two experimental antibody drugs, after both drug candidates suffered setbacks in clinical trials.The CARDIO-TTRansform trial was designed to examine the role of Wainua, a gene silencer treatment, on top of today’s stand